Xinhua Pharmaceutical Stock Bar

Xinhua Pharmaceutical (000756) Stock Bar discusses the fluctuations of Xinhua Pharmaceutical stocks.

Xinhua Pharmaceutical (full name: Shandong Xinhua Pharmaceutical Co., Ltd.) was founded in 1993 and is headquartered in Shandong.

In December 1996, Xinhua Pharmaceutical used Hong Kong as its listing location and publicly issued H shares of the People's Republic of China and the State. In July 1997, Xinhua Pharmaceutical used Shenzhen as its listing location and publicly issued A shares of the People's Republic of China and the State. In November 1998, the company was converted into a foreign-invested joint-stock company with the approval of the People's Republic of China and the Ministry of Foreign Trade and Economic Cooperation.

On March 12, 2018, Xinhua Pharmaceutical and Alibaba *** signed a framework cooperation agreement.

1. Company background

In Zibo, an important industrial city on the Shandong Peninsula in eastern China, there is a modern medical city with more than half a century of development history and assets of more than 3 billion yuan. , China's largest chemical synthetic drug base with an annual output of tens of thousands of tons of chemical raw materials, billions of preparations (tablets, granules), hundreds of thousands of tons of chemical products and a large number of chemical anti-corrosion equipment, plays the important role of the vanguard of China's pharmaceutical industry and is known as Known as China's pharmaceutical giant, it is expected to be China's national pharmaceutical brand! This is Shandong Xinhua Pharmaceutical Group Co., Ltd.

2. Creation History

Shandong Xinhua Pharmaceutical Group Corporation was developed on the basis of the former national super-large enterprise Shandong Xinhua Pharmaceutical Co., Ltd. and was founded on March 31, 1995. At the founding meeting, Zibo State-owned Assets Management Committee authorized Xinhua Group to operate state-owned assets within its jurisdiction. On December 28, 1998, Xinhua Pharmaceutical Group Corporation and Lukang Pharmaceutical Group reorganized their assets to achieve a strong alliance and established Xinhua Lukang Pharmaceutical Group.

3. Enterprise scale

Shandong Xinhua Pharmaceutical Group has total assets of more than 3 billion yuan and nearly 10,000 employees. It is known as the largest production and export base of antipyretic and analgesic drugs in the country. It is also an important manufacturer of anti-infective drugs, cardiovascular and cerebrovascular drugs, central nervous system drugs, hormonal drugs and anthelmintic drugs. Since its establishment in 1995, it has maintained a synchronous, high-speed and stable increase in speed efficiency of more than 10%. It has a national-level enterprise technology development center with an annual output of more than 20,000 tons of chemical raw materials, hundreds of thousands of tons of chemical products, and 6 billion tablets (grains and tubes) of various preparations. The export volume of chemical raw materials accounts for more than 60% of the total output. . In the national pharmaceutical industry, Xinhua Pharmaceutical Group has been listed among the 500 largest and most profitable enterprises in the country for many years. It is now one of the 300 state-owned large and medium-sized enterprises supported by the country, and one of the eight major enterprise groups focused on development by the Shandong Provincial Government. one.